Order Article Reprints

Gayed J, Diya O, Lowry FS, Xu X, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Lu C, et al. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial. Vaccines. 2024; 12(2):118. https://doi.org/10.3390/vaccines12020118

Gayed, Juleen, Oyeniyi Diya, Francine S. Lowry, Xia Xu, Vishva Bangad, Federico Mensa, Jing Zou, Xuping Xie, Yanping Hu, Claire Lu, and et al. 2024. "Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial" Vaccines 12, no. 2: 118. https://doi.org/10.3390/vaccines12020118

Gayed, J., Diya, O., Lowry, F. S., Xu, X., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Lu, C., Cutler, M., Belanger, T., Cooper, D., Koury, K., Anderson, A. S., Türeci, Ö., Şahin, U., Swanson, K. A., Modjarrad, K., ... Kitchin, N., on behalf of the C4591054 Study Group. (2024). Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial. Vaccines, 12(2), 118. https://doi.org/10.3390/vaccines12020118